68% of patients receiving Kymriah in the ELARA trial experienced a complete response, with an 86% overall response rate, along with a remarkable safety profile
The Portal BioRRAP will cater to all those seeking regulatory approval for biological research
First disclosure from PILOT study of Breyanzi in second-line large B-cell lymphoma underscores important role of cell therapy earlier in treatment paradigm
Phase I trial in Rwanda and South Africa aims to evaluate mRNA HIV vaccine antigen for safety and immunogenicity and strengthen regional scientific capacity
This agreement is truly remarkable for achieving greater objectives in the projects and addressing larger problems
Three RFPs now open for qualified researchers through NORD's Jayne Holtzer rare disease research grants program
AIIA partners with Startup India with the aim to identify and support innovations and start-ups working in the Ayush sector
CEPI is accelerating its programme to develop broadly protective coronavirus vaccines—a core part of US $ 3.5 billion pandemic preparedness plan
The immunogens being tested in IAVI G002 were developed by scientific teams at IAVI and Scripps Research and will be delivered via Moderna's mRNA technology
The R&D centre will endeavour to bring scientifically advanced biological, biotechnology products and novel drug delivery systems
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
